$26.61
-0.93 (-3.38%)
Open$27.54
Previous Close$27.54
Day High$27.54
Day Low$26.61
52W High$29.75
52W Low$10.86
Volume—
Avg Volume552.0K
Market Cap1.73B
P/E Ratio—
EPS$-1.08
SectorBiotechnology
Analyst Ratings
Strong Buy
20 analysts
Price Target
-32.9% upside
Current
$26.61
$26.61
Target
$17.86
$17.86
$12.55
$17.86 avg
$20.90
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 91.55M | 144.01M | 182.20M |
| Net Income | -70,089,188 | -99,229,619 | 28.41M |
| Profit Margin | -76.6% | -72.7% | 15.6% |
| EBITDA | -76,740,462 | -114,682,143 | 52.86M |
| Free Cash Flow | — | — | 21.80M |
| Rev Growth | -36.4% | -36.4% | +8.1% |
| Debt/Equity | — | — | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |